Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept plus mycophenolate mofetil and corticosteroids for active class III or IV lupus nephritis
2012-000714-11Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Abatacept + MMF + corticosteroids with Placebo + MMF + corticosteroids (2 arms). Primary endpoint: Complete renal response at Week 52. Started Feb 2013; status: completed.
02
Drugs
abatacept
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2012-000714-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000714-11.